Get started
Author

Nidhi K. Kochar

Observed names: N Kochar, Nidhi Kochar
OpenAlex ID: A5031985497
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
2021 · Lawrence Corey, Peter B. Gilbert, et al. · New England Journal of Medicine · 560
PDF
Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition
2022 · Peter B. Gilbert, Yunda Huang, et al. · Nature Medicine · 132
PDF
Phase Angle of Entrainment in Morning‐ and Evening‐Types under Naturalistic Conditions
2009 · Jonathan S. Emens, Krista Yuhas, et al. · Chronobiology International · 102
Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials
2017 · Peter B Gilbert, Michal Juraska, et al. · Statistical Communications in Infectious Diseases · 95
First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090)
2015 · Jonathan D. Fuchs, Ian Frank, et al. · Open Forum Infectious Diseases · 67
PDF
Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial
2018 · Marnie L. Elizaga, Shuying S. Li, et al. · PLoS ONE · 66
PDF
DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8 + T-Cell Responses by Interleukin-12 Plasmid DNA
2017 · Shuying S. Li, Nidhi K. Kochar, et al. · Clinical and Vaccine Immunology · 49
A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings
2021 · Nyaradzo M. Mgodi, Simbarashe Takuva, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 45
Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody
2021 · Srilatha Edupuganti, Nyaradzo Mgodi, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 31
HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial
2014 · Pierre-Alexandre Bart, Yunda Huang, et al. · Journal of Clinical Investigation · 30
PDF
Timing of Plasmid Cytokine (IL-2/Ig) Administration Affects HIV-1 Vaccine Immunogenicity in HIV-Seronegative Subjects
2011 · Lindsey R. Baden, William A. Blattner, et al. · The Journal of Infectious Diseases · 27
PDF
10 A Review of Statistical Analyses for Competing Risks
2007 · Melvin L. Moeschberger, Kevin P. Tordoff, et al. · Handbook of statistics · 8
First-in-human phase I clinical trial of a recombinant vesicular stomatitis virus (rVSV)-based preventive HIV-1 vaccine
2012 · JD Fuchs, I Frank, et al. · Retrovirology · 5
PDF
An HIV DNA Vaccine Delivered by Electroporation and Boosted by rVSV HIV-1 Gag Is Safe and Immunogenic in Healthy HIV-uninfected Adults
2014 · Christine M. Hay, Gregory J. Wilson, et al. · AIDS Research and Human Retroviruses · 3
DNA and recombinant adenovirus serotype 35 and 5 preventive HIV-1 vaccines with Env A inserts elicit cross-clade binding and V1V2 antibodies
2012 · JD Fuchs, C Morgan, et al. · Retrovirology · 3
PDF
P16-19. Statistical design and analysis of the CAVD-VIMC Elispot transfer study 001
2009 · Y Huang, A Sato, et al. · Retrovirology · 1
PDF
Extended in vivo activity of VRC01 HIV-1 prophylaxis entails initial protective efficacy and subsequent breakthrough infections
2026 · Allan C. deCamp, Michal Juraska, et al. · Science Translational Medicine
1272. Feasibility and Successful Enrollment in Proof-of-Concept Trials to Assess Safety and Efficacy of a Broadly Neutralizing Monoclonal Antibody, VRC01, to Prevent HIV-1 Acquisitionin in Uninfected Individuals
2019 · Srilatha Edupuganti, Nyaradzo M Mgodi, et al. · Open Forum Infectious Diseases
Works count: 18
Citation count: 1,224
H-index: 11
I10-index: 11
Year
Topic
Type